refractory/relapsed multiple myeloma
Conditions
Brief summary
Estimation of the DoR at 18 months from the combination therapy (24 months from the beginning of Te monotherapy).
Detailed description
Response at cycles 5 and every 3 cycles according to the IMWG criteria (15), PFS at 18 months from beginning of therapy with Te and ALI, Overall Survival at 24 months from the beginning of therapy with Te, Safety profile overall and with a focus on CRS according to ASTCT (16) and ICANS according to ASTCT (16)
Interventions
DRUGTECLISTAMAB
Sponsors
Fondazione Gimema Franco Mandelli Onlus
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Estimation of the DoR at 18 months from the combination therapy (24 months from the beginning of Te monotherapy). | — |
Secondary
| Measure | Time frame |
|---|---|
| Response at cycles 5 and every 3 cycles according to the IMWG criteria (15), PFS at 18 months from beginning of therapy with Te and ALI, Overall Survival at 24 months from the beginning of therapy with Te, Safety profile overall and with a focus on CRS according to ASTCT (16) and ICANS according to ASTCT (16) | — |
Outcome results
None listed